Close Menu

Silence

Silence Therapeutics this week announced that it is closing in on a much-needed financial shot in the arm, inking deals to raise £18.7 million ($28.6 million) through the private placement of 9.5 million shares to certain investors.

After the departure of its CEO last summer — the company’s third top executive to step down in two years — Silence Therapeutics is aiming to rebuild itself as a company with an improved business model that can help it advance drug candidates beyond phase I and realize more value

Silence Therapeutics said this week that it has received clearance from German regulators to start a phase Ib/IIa clinical trial of its lead cancer drug Atu027 in combination with the widely prescribed chemotherapeutic gemcitabine for pancreatic cancer.

Title: Cyclodextrin-Based Materials, Compositions, and Uses Related Thereto
Patent Number: 8,357,377
Filed: Oct. 8, 2003

People: Michael Khan

Premium

Silence Therapeutics has named Michael Khan as its chief medical officer.
Khan has served as the company's chief medical advisor since last September.

Silence Therapeutics last month released its financial results for the first six months of 2012, reporting a sharply increased net loss on charges related to its decision to drop its license to certain RNAi intellectual property.

Silence Therapeutics has appointed Michael Khan as its new chief medical adviser. He will also serve on the company's board of directors.
Khan is an associate professor of medicine at the University of Warwick.

Silence Therapeutics this week announced that it has generated preclinical data showing that its acute lung injury drug Atu111 could boost the survival of mice infected with pneumonia when combined with antibiotics.

Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.

This story has been updated to include information about Arrowhead Research's reverse stock split.

Pages

The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.

Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.

The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.

In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.